Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals to Present at Upcoming June 2019 Conferences

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Arrowhead Pharmaceuticals to Present at Upcoming June 2019 Conferences

Pasadena. CA | Posted on June 2nd, 2019

Jefferies 2019 Global Health Care Conference– New York, June 4-7, 2019

June 6, 9:30 a.m. EDT –Vincent Anzalone, CFA, Arrowhead’s vice president of investor relations, will participate in a fireside chat presentation with Maury Raycroft, Ph.D., Jefferies research analyst

Science of HBV Cure 2019 – Singapore, June 7-8, 2019

June 8, 2:30 p.m. SGT – Bruce Give, M.D., Arrowhead’s chief operating officer and head of R&D, will deliver an oral presentation titled, “RNAi: Pulling Us Toward Finite Therapy”

Alpha-1 National Conference– Orlando, FL, June 21-23, 2019

June 21 –James Hamilton, M.D., Arrowhead’s vice president of clinical development, will deliver an oral presentation titled, “ARO-AAT for Liver Disease in Alpha-1 Antitrypsin Deficiency: Progress in Clinical Development”

A copy of the presentation materials and webcast links, if the presentation is being webcast, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Self-driving microrobots December 10th, 2019

CEA-Leti Thin-Film Batteries Target Extended Applications and Improved Performance in Medical Implants: IEDM 2019 Paper Reports Millimeter-Scale TFBs Exhibit the Best Performance In Both Energy and Power Densities December 10th, 2019

Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million December 7th, 2019

'Buildings' in human bone may hold key to stronger 3D-printed lightweight structures December 6th, 2019

Possible Futures

Self-driving microrobots December 10th, 2019

CEA-Leti Thin-Film Batteries Target Extended Applications and Improved Performance in Medical Implants: IEDM 2019 Paper Reports Millimeter-Scale TFBs Exhibit the Best Performance In Both Energy and Power Densities December 10th, 2019

'Buildings' in human bone may hold key to stronger 3D-printed lightweight structures December 6th, 2019

Artificial cells act more like the real thing December 6th, 2019

Nanomedicine

Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million December 7th, 2019

Artificial cells act more like the real thing December 6th, 2019

Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock December 5th, 2019

Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock December 3rd, 2019

Announcements

Self-driving microrobots December 10th, 2019

CEA-Leti Thin-Film Batteries Target Extended Applications and Improved Performance in Medical Implants: IEDM 2019 Paper Reports Millimeter-Scale TFBs Exhibit the Best Performance In Both Energy and Power Densities December 10th, 2019

Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million December 7th, 2019

'Buildings' in human bone may hold key to stronger 3D-printed lightweight structures December 6th, 2019

Events/Classes

"Inverse Design for Self-Assembly: Patchy Particles, Machine Learning, and the Truth about Entropy" December 3rd, 2019

Arrowhead Pharmaceuticals to Participate in Upcoming December 2019 Conferences November 26th, 2019

Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results November 25th, 2019

Onto Innovation to Participate in the 8th Annual NYC Investor Summit 2019 November 21st, 2019

Nanobiotechnology

Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million December 7th, 2019

Artificial cells act more like the real thing December 6th, 2019

Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock December 5th, 2019

Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock December 3rd, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project